TITLE

Dr. Reddy's Balaglitazone Data Solid in Phase III

PUB. DATE
January 2010
SOURCE
Bioworld Week;1/11/2010, Vol. 18 Issue 2, p2
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article reports on the solid top-line data gathered by pharmaceutical companies Dr. Reddy's Laboratories Ltd. and Nordic Bioscience AS from the Phase III trial of the insulin sensitizer balaglitazone. It presents findings for the efficacy of Takeda Pharmaceuticals Co. Ltd.'s Actos in dodging diabetes bad side effects. It also notes the plan of the companies on the release of the Phase III results.
ACCESSION #
47565456

 

Related Articles

  • Rheoscience, Dr. Reddy's Move Balaglitazone Into Phase III Trial. Sheridan, Cormac // BioWorld International;8/8/2007, Vol. 12 Issue 32, p1 

    This article reports on the Phase III clinical trial of balaglitazone, a partial agonist of peroxisome proliferator-activated receptor gamma, in patients with Type II diabetes, which is being conducted by Rheoscience A/S and Dr. Reddy's Laboratories Ltd. Balaglitazone is a member of the...

  • 'Reddy' for Another PPAR Drug? Balaglitazone Solid in Phase III. Osborne, Randy // BioWorld International;1/6/2010, Vol. 15 Issue 1, p3 

    The article reports on the positive findings of the first phase III trial of Dr. Reddy's Laboratories Ltd. and Nordic Bioscience A/S for balaglitazone, a peroxisome proliferator-activated receptor (PPAR)-agonist for diabetes. The trial has revealed that balaglitazone was able to avoid the bad...

  • Lead GPR40 agonist bites the dust.  // Nature Reviews Drug Discovery;Feb2014, Vol. 13 Issue 2, p91 

    The article reports on drug manufacturer Takeda Pharmaceutical Co. Ltd.'s termination of its G protein-coupled receptor (GPR) 40 agonist, fasiligram, due to its failure and inducement of liver toxicity affecting its potential role as an antidiabetic drug.

  • Takeda Acquires LigoCyte Pharma.  // Contract Pharma;Nov/Dec2012, Vol. 14 Issue 9, p94 

    The article offers information related to pharmaceutical industry acquisition. It says that LigoCyte Pharmaceuticals Inc. will be acquired by Takeda Pharmaceutical Co. Ltd. as part of the company's expansion for its vaccine business. It mentions that Pfizer Inc. has entered an option and merger...

  • Dr Reddy's Laboratories--good show.  // Chemical Business;Jul98, Vol. 12 Issue 7, p116 

    Reports on the financial performance of the Dr. Reddy's Laboratories company in fiscal year 1997-98. Turnover growth of the formulations business; Formulations sales in India; Sales of the bulk drugs business.

  • Dr Reddy's to expand bulk drug activities.  // Chemical Business;Aug95, Vol. 9 Issue 1, p30 

    Reports that Indian company Dr. Reddy's Lab is contemplating expanding its activities in the fields of bulk drugs as also formulations. Set up of unit by company; Costs; Other expansion by company.

  • Five pronged strategy. Desai, Suresh Thakur // Chemical Business;Dec97, Vol. 11 Issue 5, p23 

    Reports on the five-pronged strategy for bulk actives by Hyderabad, India-based Dr. Reddy's Laboratories to sustain its profitability.

  • Dr. Reddy's seeks global patents for 4 products.  // Chemical Business;Jun95, Vol. 8 Issue 11, p64 

    Reports on Dr. Reddy's Laboratories' efforts to obtain world-wide patents for four of its products. Search for joint venture partners in Russia and China; Increased demand for cheap generic substitutes in the United States.

  • Dr. Reddy's Laboratories Inc.  // Pharmaceutical Technology;Dec2010 Supplement, p92 

    The article presents the corporate profile of Dr. Reddy's Laboratories Inc., located in Bridgewater, New Jersey, where it was established in 1984 and has 14,000 active employees.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics